Anti-tumor therapy strategy of CAR-T cells based on stem cell memory and central memory cells
Cancer immunotherapy including immune checkpoint inhibitors and adoptive cell therapy has gained revolutionary success in the treatment of hematologic tumors;however,it only gains limited success in solid tumors.For example,chimeric antigen receptor T(CAR-T)cell therapy has shown significant effects and potential for curing patients with B-cell malignancies.In contrast,it remains a challenge for CAR-T cell therapy to gain similar success in solid tumors.The anti-tumor effect of endogenous or adoptively transferred tumor-specific T cells depends largely on their differentiation status.T cells at early differentiation stage show better anti-tumor therapeutic effects than fully differentiated effector T cells.In cancer patients,the persistence of tumor-specific T cells with the stem cell memory or precursor phenotype is significantly associated with improved therapeutic outcomes;therefore,adoptively transfered CAR-T cells with stem cell memory and/or central memory is expected to gain better anti-tumor effects.Herein we focused on the in vitro optimized culture and expansion system to obtain CAR-T cells with stem cell memory or central memory phenotype for the review.
Tumor immunotherapychimeric antigen receptor T cellsadoptive cell therapystem cell memory T cellsmetabolic fitnessepigenetic regulationreview
万方数据
维普
